Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, has announced its participation in three upcoming investor conferences:
1. H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 4:00 p.m. ET in New York
2. Jefferies Global Healthcare Conference on June 5, 2025, at 9:55 a.m. ET in New York
3. Goldman Sachs Global Healthcare Conference on June 11, 2025, at 10:40 a.m. ET in Miami Beach
The company will conduct one-on-one meetings at all events. Live webcasts and 90-day archived recordings will be available on Phathom's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PHAT gained 7.08%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June:
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ in New York, NY
Date: Tuesday, May 20, 2025
Live Webcast: 4:00 p.m. ET
Company to participate in one-on-one meetings throughout the conference
Jefferies Global Healthcare Conference in New York, NY
Date: Thursday, June 5, 2025
Live Webcast: 9:55 a.m. ET
Company to participate in one-on-one meetings throughout the conference
Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami Beach, FL
Date: Wednesday, June 11, 2025
Live Webcast: 10:40 a.m. ET
Company to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When is Phathom Pharmaceuticals (PHAT) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I access Phathom Pharmaceuticals' (PHAT) investor conference webcasts?
Which investor conferences is Phathom Pharmaceuticals (PHAT) attending in May and June 2025?
What type of meetings will Phathom Pharmaceuticals (PHAT) conduct at these investor conferences?
